

# Robert S Rosenson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5076189/publications.pdf>

Version: 2024-02-01

298  
papers

21,532  
citations

13854

67  
h-index

10441

139  
g-index

343  
all docs

343  
docs citations

343  
times ranked

21325  
citing authors

#	ARTICLE	IF	CITATIONS
1	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 53, 1573-1619.	1.2	1,797
2	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation, 2009, 119, 2250-2294.	1.6	992
3	Antiatherothrombotic Properties of Statins. JAMA - Journal of the American Medical Association, 1998, 279, 1643.	3.8	838
4	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	13.9	778
5	Cholesterol Efflux and Atheroprotection. Circulation, 2012, 125, 1905-1919.	1.6	772
6	Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature Reviews Cardiology, 2016, 13, 48-60.	6.1	547
7	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. Journal of the American College of Cardiology, 2014, 63, 2541-2548.	1.2	465
8	Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. Circulation, 2009, 119, 931-939.	1.6	427
9	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA - Journal of the American Medical Association, 2016, 315, 1580.	3.8	420
10	HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events. Clinical Chemistry, 2011, 57, 392-410.	1.5	417
11	Evinacumab for Homozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 383, 711-720.	13.9	413
12	An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal of Clinical Lipidology, 2014, 8, S58-S71.	0.6	391
13	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology, 2008, 52, 1502-1517.	1.2	390
14	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 2008, 102, 1K-34K.	0.7	371
15	ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. Journal of the American College of Cardiology, 2012, 60, 2427-2463.	1.2	352
16	High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 484-525.	0.6	276
17	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 311, 252.	3.8	270
18	Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. American Journal of Cardiology, 2002, 90, 89-94.	0.7	269

#	ARTICLE	IF	CITATIONS
19	Statins and sepsis: multiple modifications at multiple levels. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 358-368.	4.6	268
20	Current overview of statin-induced myopathy. <i>American Journal of Medicine</i> , 2004, 116, 408-416.	0.6	259
21	Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1386-1395.	1.2	258
22	Myocardial injury: The acute phase response and lipoprotein metabolism. <i>Journal of the American College of Cardiology</i> , 1993, 22, 933-940.	1.2	236
23	Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. <i>Atherosclerosis</i> , 2004, 173, 1-12.	0.4	233
24	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335.	0.9	227
25	Deep learning for cardiovascular medicine: a practical primer. <i>European Heart Journal</i> , 2019, 40, 2058-2073.	1.0	218
26	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	1.2	216
27	Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. <i>Diabetes Care</i> , 2010, 33, 1395-1402.	4.3	211
28	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 618-628.	5.5	207
29	Translation of High-Density Lipoprotein Function Into Clinical Practice. <i>Circulation</i> , 2013, 128, 1256-1267.	1.6	197
30	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2525-2540.	1.2	192
31	Evinacumab in Patients with Refractory Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 2307-2319.	13.9	186
32	Effects of lipids and lipoproteins on thrombosis and rheology. <i>Atherosclerosis</i> , 1998, 140, 271-280.	0.4	182
33	Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab. <i>Journal of the American College of Cardiology</i> , 2017, 69, 471-482.	1.2	166
34	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	1.2	162
35	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	1.2	162
36	Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women. <i>Diabetes</i> , 2010, 59, 1153-1160.	0.3	157

#	ARTICLE	IF	CITATIONS
37	Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. <i>Journal of Lipid Research</i> , 2012, 53, 1767-1782.	2.0	146
38	Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 270-277.	1.2	136
39	Phospholipase A2 enzymes and the risk of atherosclerosis. <i>European Heart Journal</i> , 2012, 33, 2899-2909.	1.0	116
40	Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA). <i>Journal of Lipid Research</i> , 2012, 53, 1767-1782.	6.8	115
41	Statins: panacea for sepsis?. <i>Lancet Infectious Diseases</i> , 2006, 6, 242-248.	4.6	114
42	Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome. <i>Diabetes Care</i> , 2007, 30, 1945-1951.	4.3	111
43	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. <i>Nature Reviews Cardiology</i> , 2018, 15, 9-19.	6.1	105
44	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 618-620.	1.6	96
45	Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 131-142.	1.2	96
46	Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 495-505.	0.6	95
47	Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2017, 2, 890.	3.0	95
48	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. <i>Circulation</i> , 2004, 110, e550-3.	1.6	94
49	Adherence to Statin Therapy Among US Adults Between 2007 and 2014. <i>Journal of the American Heart Association</i> , 2019, 8, e010376.	1.6	93
50	Residual microvascular risk in diabetes: unmet needs and future directions. <i>Nature Reviews Endocrinology</i> , 2010, 6, 19-25.	4.3	92
51	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	1.0	92
52	Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2015, 66, 184-192.	1.2	91
53	Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 871-895.	0.6	89
54	The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 179-186.	1.3	89

#	ARTICLE	IF	CITATIONS
55	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. <i>JAMA Cardiology</i> , 2021, 6, 1060.	3.0	86
56	Atherosclerotic Vascular Disease Conference. <i>Circulation</i> , 2004, 109, 2613-2616.	1.6	85
57	Beginning to Understand High-Density Lipoproteins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 913-947.	1.2	85
58	Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. <i>Atherosclerosis</i> , 2002, 160, 41-48.	0.4	82
59	Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1079-1088.	1.2	82
60	Fenofibrate: treatment of hyperlipidemia and beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1319-1330.	0.6	81
61	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. <i>Circulation</i> , 2016, 133, 256-264.	1.6	80
62	Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. <i>Atherosclerosis</i> , 2002, 161, 433-439.	0.4	78
63	Antiatherothrombotic effects of nicotinic acid. <i>Atherosclerosis</i> , 2003, 171, 87-96.	0.4	78
64	Importance of Blood Rheology in the Pathophysiology of Atherothrombosis. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 339-348.	1.3	75
65	Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group1. <i>American Journal of Transplantation</i> , 2002, 2, 491-500.	2.6	71
66	Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes. <i>Current Cardiology Reports</i> , 2009, 11, 445-451.	1.3	71
67	FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 493-494.	2.3	70
68	Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2696-2706.	1.2	70
69	Dietary Patterns and Incident Heart Failure in U.S. Adults Without Known Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2036-2045.	1.2	70
70	Low HDL-C: A secondary target of dyslipidemia therapy. <i>American Journal of Medicine</i> , 2005, 118, 1067-1077.	0.6	65
71	Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 93-101.	1.3	63
72	PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, e001632.	5.1	63

#	ARTICLE	IF	CITATIONS
73	Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 411-420.	1.0	61
74	Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled study. <i>Diabetes Care</i> , 2009, 32, 1087-1091.	4.3	61
75	Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1298-1306.	1.1	59
76	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2171-2185.	1.2	59
77	Trends in the Prevalence, Awareness, Treatment and Control of High Low Density Lipoprotein-Cholesterol Among United States Adults From 1999 through 2009 through 2009 through 2010. <i>American Journal of Cardiology</i> , 2013, 112, 664-670.	0.7	58
78	Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. <i>Atherosclerosis</i> , 2016, 245, 111-117.	0.4	57
79	Cardiovascular Risks of Anemia Correction with Erythrocyte Stimulating Agents: Should Blood Viscosity Be Monitored for Risk Assessment?. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 151-160.	1.3	56
80	Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. <i>American Heart Journal</i> , 2012, 164, 672-680.	1.2	56
81	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. <i>Clinical Trials</i> , 2020, 17, 491-500.	0.7	56
82	Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. <i>European Heart Journal</i> , 2011, 32, 999-1005.	1.0	55
83	Non-Lipid-lowering effects of statins on atherosclerosis. <i>Current Cardiology Reports</i> , 1999, 1, 225-232.	1.3	53
84	Comparative study of HMG-CoA reductase inhibitors on fibrinogen. <i>Atherosclerosis</i> , 2001, 155, 463-466.	0.4	49
85	Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. <i>Clinical Therapeutics</i> , 2004, 26, 1400-1410.	1.1	49
86	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. <i>Cardiovascular Research</i> , 2018, 114, 1073-1081.	1.8	49
87	Hypertriglyceridemia and other factors associated with plasma viscosity. <i>American Journal of Medicine</i> , 2001, 110, 488-492.	0.6	48
88	High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. <i>Current Opinion in Cardiology</i> , 2002, 17, 325-331.	0.8	48
89	Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. <i>Atherosclerosis</i> , 2007, 194, e154-e164.	0.4	48
90	Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 251-264.	1.2	47

#	ARTICLE	IF	CITATIONS
91	Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. <i>Clinical Cardiology</i> , 1999, 22, 25-28.	0.7	46
92	Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates. <i>International Journal of Cardiology</i> , 2008, 124, 149-159.	0.8	45
93	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	1.3	45
94	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 364-385.	2.0	45
95	Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers. <i>Intensive Care Medicine</i> , 2004, 30, 1361-9.	3.9	43
96	Low high-density lipoprotein cholesterol and cardiovascular disease: Risk reduction with statin therapy. <i>American Heart Journal</i> , 2006, 151, 556-563.	1.2	43
97	Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. <i>Atherosclerosis</i> , 2010, 213, 1-7.	0.4	43
98	Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009. <i>American Heart Journal</i> , 2015, 170, 249-255.e2.	1.2	43
99	Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. <i>Clinical Endocrinology</i> , 2002, 57, 209-214.	1.2	42
100	The High-Density Lipoprotein Puzzle. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 777-782.	1.1	42
101	Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. <i>Atherosclerosis</i> , 2006, 185, 327-330.	0.4	41
102	Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. <i>Diabetologia</i> , 2019, 62, 948-958.	2.9	41
103	Low high density lipoprotein levels are associated with an elevated blood viscosity. <i>Atherosclerosis</i> , 1999, 146, 161-165.	0.4	39
104	Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 71-75.	1.3	39
105	Hormone Replacement Therapy Improves Cardiovascular Risk by Lowering Plasma Viscosity in Postmenopausal Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1902-1905.	1.1	38
106	Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 465-479.	1.3	38
107	Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome. <i>Circulation Research</i> , 2014, 114, 1880-1889.	2.0	38
108	Coronavirus and Cardiometabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2024-2035.	1.2	38

#	ARTICLE	IF	CITATIONS
109	Short-term reduction in bone markers with high-dose simvastatin. <i>Osteoporosis International</i> , 2005, 16, 1272-1276.	1.3	37
110	PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment. <i>Circulation</i> , 2018, 137, 1260-1269.	1.6	37
111	Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. <i>Journal of Clinical Lipidology</i> , 2014, 8, 86-93.	0.6	36
112	Ischemic Event Rates in Very-High-Risk Adults. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2496-2507.	1.2	35
113	Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. <i>Atherosclerosis</i> , 2008, 198, 381-388.	0.4	34
114	Management of Hyperlipidemia in Older Adults. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 49-58.	1.0	34
115	Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. <i>Current Opinion in Lipidology</i> , 2010, 21, 473-480.	1.2	34
116	Safety of combined pravastatin-gemfibrozil therapy. <i>American Journal of Cardiology</i> , 1994, 74, 499-500.	0.7	33
117	Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events. <i>American Journal of Medicine</i> , 2010, 123, 892-898.	0.6	33
118	Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. <i>Atherosclerosis</i> , 2009, 204, 342-344.	0.4	32
119	Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. <i>Annals of Epidemiology</i> , 2014, 24, 581-587.	0.9	32
120	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144.	0.7	32
121	Variations of whole blood viscosity using Rheologâ, a new scanning capillary viscometer. <i>Clinica Chimica Acta</i> , 2003, 332, 79-82.	0.5	31
122	Hyperinsulinemia and Homeostasis Model Assessment of Insulin Resistance as Predictors of Hypertension: A 5-Year Follow-Up Study of Korean Sample. <i>American Journal of Hypertension</i> , 2011, 24, 1041-1045.	1.0	31
123	Ability of Low Antihypertensive Medication Adherence to Predict Statin Discontinuation and Low Statin Adherence in Patients Initiating Treatment After a Coronary Event. <i>American Journal of Cardiology</i> , 2014, 114, 826-831.	0.7	31
124	Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era. <i>Journal of the American Heart Association</i> , 2020, 9, e013744.	1.6	31
125	Association between sepsis survivorship and long-term cardiovascular outcomes in adults: a systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2021, 47, 931-942.	3.9	31
126	Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. <i>Atherosclerosis</i> , 2015, 241, 176-182.	0.4	30



#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 305-313.	1.3	30
128	Evolocumab in HIV-Infected Patients With Dyslipidemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2570-2584.	1.2	30
129	Acute-Phase Reactants and Coronary Heart Disease. <i>Seminars in Vascular Medicine</i> , 2002, 02, 417-428.	2.1	29
130	Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. <i>Current Opinion in Lipidology</i> , 2002, 13, 625-630.	1.2	28
131	New Therapies for Lowering Triglyceride-Rich Lipoproteins. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1817-1830.	1.2	28
132	Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1680-1681.	1.2	27
133	Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999â€“2014. <i>Journal of the American Heart Association</i> , 2019, 8, e010640.	1.6	27
134	HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 166-173.	0.8	26
135	Treatment of severe hypertriglyceridemia lowers plasma viscosity. <i>Atherosclerosis</i> , 1998, 137, 401-405.	0.4	25
136	Avoiding the Looming Latino/Hispanic Cardiovascular Health Crisis: A Call to Action. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 238-243.	1.7	25
137	Design and Rationale of the <sc>GAUSS</sc>â€“2 Study Trial: A Doubleâ€“Blind, Ezetimibeâ€“Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (<sc>AMG</sc> 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy. <i>Clinical Cardiology</i> , 2014, 37, 131-139.	0.7	25
138	Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 233-240.	1.3	25
139	Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1864-1872.	1.2	24
140	Primary Care Physician Perspectives on Barriers to Statin Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 303-309.	1.3	24
141	Lovastatin-associated sleep and mood disturbances. <i>American Journal of Medicine</i> , 1993, 95, 548-549.	0.6	23
142	Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier. <i>American Journal of Cardiology</i> , 2009, 104, 52E-57E.	0.7	23
143	Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 525-533.	1.3	23
144	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 297-304.	1.3	23

#	ARTICLE	IF	CITATIONS
145	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes. Journal of the American College of Cardiology, 2020, 76, 1999-2010.	1.2	23
146	Sex Differences in Incident and Recurrent Coronary Events and All-Cause Mortality. Journal of the American College of Cardiology, 2020, 76, 1751-1760.	1.2	23
147	New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Current Problems in Cardiology, 2005, 30, 241-279.	1.1	22
148	Management of non-high-density lipoprotein abnormalities. Atherosclerosis, 2009, 207, 328-335.	0.4	22
149	Biological basis for statin therapy in stroke prevention. Current Opinion in Neurology, 2000, 13, 57-62.	1.8	22
150	Assessment of the 1% of Patients with Consistent &lt;math>\hat{A}>15\% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials. Cardiovascular Drugs and Therapy, 2018, 32, 175-180.	1.3	21
151	Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV-Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015. Journal of the American Heart Association, 2018, 7, e010345.	1.6	21
152	Oral $17\beta$ -estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size. Atherosclerosis, 2001, 155, 425-430.	0.4	20
153	Lp-PLA2 and risk of atherosclerotic vascular disease. Lancet, The, 2010, 375, 1498-1500.	6.3	20
154	Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults. Cardiovascular Drugs and Therapy, 2016, 30, 323-331.	1.3	20
155	Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in) Tj ETQq1 1 0.784314 rgBT /Over 0.7 20	0.7	20
156	Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries. JAMA Cardiology, 2019, 4, 865.	3.0	20
157	Existing and emerging therapies for the treatment of familial hypercholesterolemia. Journal of Lipid Research, 2021, 62, 100060.	2.0	20
158	Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. American Journal of Cardiology, 2003, 91, 878-881.	0.7	19
159	Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovascular Drugs and Therapy, 2017, 31, 187-195.	1.3	19
160	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovascular Drugs and Therapy, 2018, 32, 365-372.	1.3	19
161	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	4.3	19
162	Dissecting aneurysm of the pulmonary trunk in mitral stenosis. American Journal of Cardiology, 1986, 58, 1140-1141.	0.7	18

#	ARTICLE	IF	CITATIONS
163	Nemaline cardiomyopathy. American Journal of Cardiology, 1986, 58, 175-177.	0.7	18
164	Elevated blood viscosity in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2001, 31, 52-57.	1.6	18
165	Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects. Translational Research, 2005, 145, 83-87.	2.4	18
166	Cardiovascular Disease Prevention and Care in Latino and Hispanic Subjects. Endocrine Practice, 2007, 13, 77-85.	1.1	18
167	Efficacy and Safety of Rosuvastatin 5Âmg in Combination with Fenofibric Acid 135Âmg in Patients with Mixed Dyslipidemia â€“ A Phase 3 Study. Cardiovascular Drugs and Therapy, 2010, 24, 421-428.	1.3	18
168	Varespladib methyl in cardiovascular disease. Expert Opinion on Investigational Drugs, 2010, 19, 1245-1255.	1.9	18
169	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. American Heart Journal, 2020, 219, 70-77.	1.2	18
170	Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Current Opinion in Cardiology, 2004, 19, 480-487.	0.8	17
171	Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 2011, 25, 47-57.	1.3	17
172	Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Cardiovascular Diabetology, 2021, 20, 94.	2.7	17
173	Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. Cardiovascular Drugs and Therapy, 2015, 29, 41-50.	1.3	16
174	New Technologies Personalize Diagnostics and Therapeutics. Current Atherosclerosis Reports, 2010, 12, 184-186.	2.0	15
175	Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome. Cardiovascular Drugs and Therapy, 2011, 25, 539-544.	1.3	15
176	Medical Misinformation: Vet the Message!. Journal of the American Heart Association, 2019, 8, e011838.	1.6	15
177	Triglyceride reduction in secondary atherosclerotic cardiovascular disease prevention: core concepts in contemporary therapeutic targeting. European Heart Journal, 2020, 41, 1521-1522.	1.0	15
178	The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids in Health and Disease, 2021, 20, 72.	1.2	15
179	Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19. Cardiovascular Drugs and Therapy, 2022, 36, 1165-1173.	1.3	15
180	Physiciansâ€™ interpretation of â€œclass effectsâ€•. Journal of the American College of Cardiology, 2002, 40, 19-26.	1.2	14

#	ARTICLE	IF	CITATIONS
181	Statin therapy: new therapy for cardiac microvascular dysfunction. <i>European Heart Journal</i> , 2003, 24, 1993-1994.	1.0	14
182	Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. <i>Atherosclerosis</i> , 2004, 177, 77-81.	0.4	14
183	Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. <i>Current Opinion in Cardiology</i> , 2005, 20, 313-317.	0.8	14
184	Recombinant High-Density Lipoprotein Formulations. <i>Current Atherosclerosis Reports</i> , 2011, 13, 81-87.	2.0	14
185	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 349-358.	1.3	14
186	Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 189-199.	1.3	14
187	Hypertriglyceridemia and Coronary Heart Disease Risk. <i>Cardiology in Review</i> , 1999, 7, 342-348.	0.6	13
188	Lipoprotein Associated Phospholipase A2 Inhibition Reduces Generation of Oxidized Fatty Acids. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 55-58.	1.3	13
189	Treatment with Aspirin and Dipyridamole is More Effective than Aspirin in Reducing Low Shear Blood Viscosity. <i>Microcirculation</i> , 2008, 15, 615-620.	1.0	13
190	Initial combination therapy with metformin plus colessevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. <i>Journal of Clinical Lipidology</i> , 2012, 6, 318-324.	0.6	13
191	Awareness, Treatment, and Control of LDL Cholesterol Are Lower Among U.S. Adults With Undiagnosed Diabetes Versus Diagnosed Diabetes. <i>Diabetes Care</i> , 2013, 36, 2734-2740.	4.3	13
192	PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. <i>PLoS ONE</i> , 2019, 14, e0210808.	1.1	13
193	Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults. <i>Journal of Headache and Pain</i> , 2021, 22, 124.	2.5	13
194	Blood hyperviscosity in acute and recent COVID-19 infection. <i>Clinical Hemorheology and Microcirculation</i> , 2022, , 1-7.	0.9	13
195	Lipoprotein-associated phospholipase A <sub>2</sub> and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis. <i>Vascular Medicine</i> , 2017, 22, 5-12.	0.8	12
196	Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 307-313.	1.3	12
197	Statin Use Following Hospitalization Among Medicare Beneficiaries With a Secondary Discharge Diagnosis of Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	11
198	Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 65-74.	1.3	11

#	ARTICLE	IF	CITATIONS
199	Old Drugs for New Indications in Cardiovascular Medicine. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 223-232.	1.3	11
200	Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2019, 123, 1202-1207.	0.7	11
201	Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction. <i>Journal of Clinical Lipidology</i> , 2020, 14, 260-270.	0.6	11
202	Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 479-489.	1.3	11
203	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 677-690.	1.3	11
204	Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. <i>Journal of the American Heart Association</i> , 2021, 10, e019254.	1.6	11
205	The Residual Risk Odyssey. <i>Journal of the American College of Cardiology</i> , 2021, 78, 434-436.	1.2	11
206	Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 402-405.	1.4	11
207	Clinical trials report. <i>Current Atherosclerosis Reports</i> , 2006, 8, 219-222.	2.0	10
208	Adenosine transport, erythrocyte deformability and microvascular dysfunction: An unrecognized potential role for dipyridamole therapy. <i>Clinical Hemorheology and Microcirculation</i> , 2010, 44, 193-205.	0.9	10
209	Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 443-451.	1.3	10
210	Egg yolk, source of bad cholesterol and good lipids?. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 548-549.	2.2	10
211	Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. <i>Atherosclerosis</i> , 2001, 159, 225-230.	0.4	9
212	Elevated coronary whole blood viscosity in acute coronary syndrome patients. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 55, 85-94.	0.9	9
213	Secular changes in rates of coronary heart disease, fatal coronary heart disease, and out-of-hospital fatal coronary heart disease. <i>International Journal of Cardiology</i> , 2014, 174, 436-439.	0.8	9
214	Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 29-36.	1.3	9
215	Systematic Review of Methods Used for the Microvascular Assessment of Peripheral Arterial Disease. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 301-310.	1.3	9
216	Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 1048-1057.	1.2	9

#	ARTICLE	IF	CITATIONS
217	Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. <i>Journal of Clinical Lipidology</i> , 2021, 15, 665-673.	0.6	9
218	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e020893.	1.6	9
219	Gemfibrozil-lovastatin-associated myalgia. <i>American Journal of Cardiology</i> , 1993, 71, 497.	0.7	8
220	Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 256-262.	0.9	8
221	Association between Ischemic Stroke and Vascular Shear Stress in the Carotid Artery. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
235	Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. <i>American Heart Journal</i> , 2018, 197, 62-69.	1.2	6
236	Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. <i>American Heart Journal</i> , 2020, 220, 203-212.	1.2	6
237	A new phenotypic classification system for dyslipidemias based on the standard lipid panel. <i>Lipids in Health and Disease</i> , 2021, 20, 170.	1.2	6
238	Measure for measure—sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 72-73.	2.9	5
239	Fenofibrate abrogates postprandial blood viscosity among hypertriglyceridemia subjects with the metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2009, 3, 17-23.	1.8	5
240	Vascular biomarkers in the metabolic syndrome. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 209-215.	1.5	5
241	After FRANCIS: next steps in the clinical evaluation of varespladib methyl. <i>Future Cardiology</i> , 2011, 7, 11-18.	0.5	5
242	Clinical Trials of HDL Cholesterol—Raising Therapy: What Have We Learned About the HDL Hypothesis from AIM-HIGH?. <i>Current Atherosclerosis Reports</i> , 2012, 14, 190-192.	2.0	5
243	Lipoprotein Measurements in Patients Infected with HIV: Is Cholesterol Content of HDL and LDL Discordant with Particle Number?. <i>Journal of Clinical Lipidology</i> , 2014, 8, 332-333.	0.6	5
244	New Challenges for HDL-Modifying Therapies as a Strategy to Lower Cardiovascular Disease Events in Statin-Treated Patients. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 1-3.	1.3	5
245	Trial designs for statin muscle intolerance. <i>Current Opinion in Lipidology</i> , 2017, 28, 488-494.	1.2	5
246	CETP inhibition improves the lipid profile but has no effect on clinical cardiovascular outcomes in high-risk patients. <i>Evidence-Based Medicine</i> , 2017, 22, 184-185.	0.6	5
247	Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 453-461.	1.3	5
248	Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2971-2975.	1.2	5
249	Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2020, 14, 636-638.	0.6	5
250	Assessing Coronary Heart Disease Risk and Managing Lipids. <i>Nurse Practitioner</i> , 2001, 26, 30-32, 34, 37-41.	0.2	5
251	Statin in the perioperative period. <i>F1000Research</i> , 2019, 8, 688.	0.8	5
252	Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment. <i>Atherosclerosis</i> , 1998, 140, 167-172.	0.4	4

#	ARTICLE	IF	CITATIONS
253	When Clinical Trials Fail to Address Treatment Gaps: The Failure of Niacin-Laropiprant to Reduce Cardiovascular Events. <i>Current Atherosclerosis Reports</i> , 2013, 15, 332.	2.0	4
254	Integrated Measure for Atherogenic Lipoproteins in the Modern Era. <i>Journal of the American College of Cardiology</i> , 2016, 67, 202-204.	1.2	4
255	Healthcare Utilization and Statin Reinitiation Among Medicare Beneficiaries With a History of Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	4
256	Treatment of Hypertension in Metabolic Syndrome Subjects with Amlodipine and Olmesartan—Effects on Oxidized Non-Esterified Free Fatty Acids and Cytokine Production. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 289-294.	1.3	3
257	Refining Lipoprotein(a) Associated Cardiovascular Risk in Women. <i>Journal of the American College of Cardiology</i> , 2018, 72, 297-299.	1.2	3
258	Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV. <i>Cardiovascular Drugs and Therapy</i> , 2020, , 1.	1.3	3
259	Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Kidney Medicine</i> , 2021, 3, 722-731.e1.	1.0	3
260	Exercise Training Improves Muscle Performance and Quality of Life in Patients With Statin Muscle Symptoms. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2038-2041.	1.2	3
261	Trends in High-Intensity Statin Therapy After Myocardial Infarction Among U.S. Adults, 2011-2019. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1870-1872.	1.2	3
262	Basic mechanisms of stroke prevention with lipid-lowering therapy. <i>Current Atherosclerosis Reports</i> , 2000, 2, 120-125.	2.0	2
263	Preanalytical sources of measurement error: The conundrum of the homocysteine hypothesis. <i>Atherosclerosis</i> , 2007, 194, 520.	0.4	2
264	Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 98-100.	3.3	2
265	Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies. <i>Journal of Clinical Lipidology</i> , 2012, 6, 534-544.	0.6	2
266	Clinical Trials Update Esc Congress 2011. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 77-84.	1.3	2
267	Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2-IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 942-943.	1.2	2
268	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 70, 685-686.	1.2	2
269	Optimizing Cholesterol Management Improves the Benefits of Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1451-1454.	1.2	2
270	Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. <i>Journal of Clinical Lipidology</i> , 2020, 14, 720-729.	0.6	2



#	ARTICLE	IF	CITATIONS
271	The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	2
272	Association of total VLDL particle concentrations with elevated blood viscosity in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 183, 109180.	1.1	2
273	Statins and sepsis: panacea or Pandora's box? â€œ Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 80-81.	4.6	1
274	SPARCL: Statin therapy for stroke patients is not crystal clear. <i>Current Atherosclerosis Reports</i> , 2007, 9, 213-215.	2.0	1
275	Glycated proteins and cardiovascular disease in glucose intolerance and type 2 diabetes. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 43-46.	0.8	1
276	A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: Lessons from GOLDN. <i>Current Atherosclerosis Reports</i> , 2009, 11, 161-163.	2.0	1
277	Lipoprotein Measurement in Patients Infected with HIV: Is Cholesterol Content of HDL and LDL Discordant with Particle Number?. <i>Journal of Clinical Lipidology</i> , 2016, 10, 693.	0.6	1
278	Small triumph for fenofibrate therapy in dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2017, 14, 131-132.	6.1	1
279	RE: Praluent (Alirocumab)-Induced Renal Injury. <i>Journal of Pharmacy Practice</i> , 2018, 31, 138-139.	0.5	1
280	Cardiovascular Outcomes in Persons With HIV and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 531-533.	1.2	1
281	One-year statin persistence and adherence in adults with HIV in the United States. <i>Journal of Clinical Lipidology</i> , 2021, 15, 181-191.	0.6	1
282	The Enigma of PCSK9 Regulation. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1450-1452.	1.2	1
283	Comparison of two whole blood viscometers: implications for cardiovascular and thrombosis research. <i>Thrombosis and Haemostasis</i> , 2004, 92, 225-6.	1.8	1
284	Cardiovascular disease in older people. <i>Lancet</i> , The, 1998, 351, 1595.	6.3	0
285	Off-target toxicity: Risks associated with adrenal corticoid activation in ILLUMINATE. <i>Current Atherosclerosis Reports</i> , 2008, 10, 227-229.	2.0	0
286	Role of statin therapy in stroke prevention. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 131-139.	2.3	0
287	Simultaneous Achievement of Optimal Lipid Targets with the Combination of Rosuvastatin 5 mg + Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2010, 4, 206-207.	0.6	0
288	Translating HDL Science to Clinical Practice. <i>Journal of Clinical Lipidology</i> , 2011, 5, S6-S7.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Systemic Inflammation and the Dynamics of HDL Cholesterol—Associated Residual Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2011, 13, 187-189.	2.0	0
290	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2770.	1.2	0
291	USE OF RECOMMENDED AND CONTRAINDICATED STATINS IN HIV PATIENTS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1760.	1.2	0
292	INTENSITY OF LIPID LOWERING THERAPY AMONG PATIENTS WITH POLYVASCULAR DISEASE: INSIGHTS FROM THE GOULD REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 241.	1.2	0
293	LIPID-LOWERING THERAPY IN DIFFERENT REGIONS OF THE UNITED STATES: INSIGHTS FROM GETTING TO AN IMPROVED UNDERSTANDING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND DYSLIPIDEMIA MANAGEMENT (GOULD): A REGISTRY OF HIGH CARDIOVASCULAR RISK PATIENTS IN THE UNITED STATES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1834.	1.2	0
294	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1503-1504.	1.2	0
295	Use of Lipid-Lowering Therapies in Patients with CKD and ASCVD: A 1-Year Update From GOULD—. <i>Journal of Clinical Lipidology</i> , 2020, 14, 603-604.	0.6	0
296	Physician Characteristics and Attitudes towards Lipid-Lowering Treatment and Variability in Implementation of Guidelines: Insights from the Getting to an Improved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD) Reg. <i>Journal of Clinical Lipidology</i> , 2020, 14, 607-608.	0.6	0
297	Visceral Adipose Tissue: At the Intersection of Lipoprotein Associated CV Risk. <i>Global Heart</i> , 2020, 8, 281.	0.9	0
298	Use of lipid-lowering therapies in patients with CKD and ASCVD: A 1-year update from GOULD. <i>Journal of Clinical Lipidology</i> , 2021, 15, e1.	0.6	0